Therapy of human papillomavirus infection and associated epithelial tumors

Intervirology

Volumn 40, Issue 5-6, 1997, Pages 368-377

  Gross, G ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Cidofovir; HPV associated epithelial tumors; Imiquimod; Immunotherapy; Interferon; Laser; Vaccines

Indexed keywords

ANTIVIRUS AGENT; CIDOFOVIR; IMIQUIMOD;

CARBON DIOXIDE LASER; CONDYLOMA; CONDYLOMA ACUMINATUM; DISEASE ASSOCIATION; EPITHELIUM TUMOR; LARYNX PAPILLOMATOSIS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; VACCINE PRODUCTION; VERRUCA VULGARIS; WART VIRUS;

AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; CONDYLOMATA ACUMINATA; CYTOSINE; HUMANS; INTERFERON INDUCERS; INTERFERONS; LASERS; NEOPLASMS, GLANDULAR AND EPITHELIAL; ORGANOPHOSPHORUS COMPOUNDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PHOSPHONIC ACIDS; TUMOR VIRUS INFECTIONS; VACCINES, SYNTHETIC;

EID: 2642712490     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000150569     Document Type: Article

References (92)

1. Phelps WC, Alexander KA: Antiviral therapy for human papillomaviruses: Rationale and prospects, Ann Intern Med 1995:123:368-382.
2. Van Cutsem E, Snoeck R, van Ranst M, et al: Successful treatment of squamous papilloma of the hypopharynx-csophagus by local injections of ((5)-l-(3-hydroxy-2 phosphonylmcthoxypro-pyl) cytosine, J Med 1995:45:230-235.
3. Dc Clercq E, Holy A, Rosenberg J, et al: A novel selective broad-spectrum anti-DNA virus agent, Nature 1986;323:464-467.
4. Kriesel J, Douglas J, Coray I, et al: A phase I/ll study of cidofovir topical gel for refractory condyloma acuminatum in patients with HIV infection, Fourth Conference on Retroviruses and Opportunistic Infections, Washington, January 1997.
5. Kraus SJ, Slone KM: Management of genital infection caused by human papillomavirus, Rev Infect Dis 1990; 12(suppl):S620-632.
6. Gross G: Interferons; in Eisner P, Eichntann A (eds): Sexually Transmitted Diseases, Advances in Diagnosis and Treatment, Curr Probl Dermatol, Basel, Karger, 1996. vol 24. pp 233-246.
7. Gross G, Rogozinski T, Schofer H, et al: Recombinant interferon beta gel as an adjuvant in the treatment of recurrent genital warts: Results of a placebo-controlled double-blind study in 120 patients, J Interferon Res 1994; 14(suppl I): 151.
8. Gross G: Treatment of human papillomavirus infection; in Mindel A (ed): Genital Warts, Human Papillomavirus Infection, London, Arnold, 1995. pp 198-236.
9. Gross G, Tyring SK, von Krogh G, Barrasso R: External genitalia: Treatment; in Gross G, Barrasso R (eds): Human Papilloma Virus Infection, A Clinical Atlas, Berlin, Ullstein Mosby, 1997. pp 364-376.
10. Gross G, von Krogh G, Barrasso R: Therapy -Genitoanal lesions: in Gross G, von Krogh G (eds): Human Papillomavirus Infections in Dermatovenerology, 1997. Boca Raton, CRC Press, pp 389-416.
11. Schneider A: Natural history of genital papillomavirus infections, Intcrvirology 1994:37: 201-214.
12. Messing AM, Epstein WL: Natural history of warts, Arch Dermatol 1963:87:306-310.
13. Tagami H, Ogino A, Tagigawa M, et al: Regression of plane w'arts following spontaneous inflammation, A hislopathological study, Br J Dermatol 1974:90:147-154.
14. Benton C, Shahidullah H, Hunter J: Human papillomavirus in the immunosupprcssed, Papillomavirus Rep 1992:3:23-26.
15. Morison WL: Viral warts, herpes simplex and herpes zoster in patients with secondary immune deficiencies and neoplasms, Br J Dermatol 1975;92:625-630.
16. Jablonska S, Orth G: Epidermodysplasia verruciformis, Clin Dermatol 1985:3:83-96.
17. Aloub ML Barr BB, McLaren KM, et al: Human papillomavirus infection and cervical in-traepithelial neoplasia in women with renal allografts, Br Med J 1989;298:153-156.
18. Halpcrt R, Frachter RG, Sedlis A, et al: Human papillomavirus and lower genital tract neoplasia in renal transplant patients, Obstet Gynecol 1986:68:251-258.
19. Connor ME, Stem PL: Loss of MHC class I expression in cervical carcinoma, Int J Cancer 1990:46:1029-1031.
20. Hughes RG, Norval M, Howie SE: Expression of major histocompatibility class II antigens by Langcrhans’ cells in cervical intraepithelial neoplasia, J Clin Pathol 1988:41:253-259.
21. Viac J, Soler C, Chardonnct Y, et al: Expression of immune associated surface antigens of keratinocytes in human papillomavirus-derived lesions, Immunobiology 1993:188:393-396.
22. Jochmus I, Durst M, Reid R, et al: Major histocompatibility complex and human papillomavirus type 16 E7 expression in high-grade vulvar lesions, Hum Pathol 1994:24:519-523.
23. Glew SS, Duggan-Keen M, Cabrera T, Stem PL: HLA class II antigen expression in human papillomavirus-associated cervical cancer, Cancer Res 1992:52:4009-4016.
24. Hawthorne RJ, Murdoch JB, MacLean AB, Mackic RM: Langcrhans’ cells and subtypes of human papillomavirus in cervical intraepithelial neoplasia, Br Med J 1988:297:643-646.
25. Cooper KD, Androphy EJ, Lowy D, Katz SI: Antigen presentation and T-cell activation in epidermodysplasia verruciformis, J Invest Dermatol 1990:94:769-776.
26. Beutncr K, Spruance S, Douglas J, et al: 1994; Double-blind, vehicle-controlled, randomized multicenter trial of 5% imiquimod cream for the treatment of genital and perianal warts (abstract), 2nd Int Congress papillomaviruses Hum Pathol, Paris
27. Gross G: Interferons in genital HPV disease: in Gross G, Jablonska S, Pfister H, Stegner HE (eds), Genital papillomavirus infections, Berlin, Springer, 1990. pp 393-412.
28. Rockley PF, Tyring SK: Interferons alpha, beta and gamma therapy of anogenital human papillomavirus infections, Pharmacol Ther 1995; 65:265-287.
29. Gross G, Roussaki A, Papendick U: Efficacy of interferons on bowenoid papulosis and other precancerous lesions, J Invest Dermatol 1990: 95:152-157.
30. Gaspari AA, Zalka AD, Payne D, et al: Successful treatment of a generalized human papillomavirus infection with granulocyte-macro-phagc colongy-slimulating factor and interferon gamma immunotherapy in a patient with a primary immunodeficiency and cyclic neutropenia, Arch Dermatol 1997:133:491-496.
31. Gross G, Roussaki A, Pfister H: Recurrent vulvar Buschke-Lowenstcin tumor-like condylo-mata acuminata and Hodgkin’s disease effectively treated with recombinant interferon al-pha-2c gel as adjuvant to electrosurgery, Curr Probl Dermatol, Basel, Karger, 1989. vol 18. pp 178-184.
32. Bomstein J, Pascal B, Abrantovici H: Treatment of a patient with vulvar vestibulitis by intramuscular interferon beta: a case report, Eur J Obstet Gvnccol Reprod Biol 1991:42: 237-239.
33. Ikic D, Bosnic N, Snicrdcl S: Double-blind clinical study with human leukocyte interferon in the therapy of condylomata acuminata, Proc Symp Clin Use Interferon, Zagreb 1975. pp 167-177.
34. Moller BR, Johannesen P, Osther IC, et al: Treatment of dysplasia of the cervical epithelium with an interferon gel, J Obstet Gynecol 1983:62:625-629.
35. Marcovici R, Perctz BA, Paldi E: Human fibroblast interferon therapy in patients with condylomata acuminata, IsrJ Med Sci 1983:19:104.
36. Vestcrinen E, Meyer B, Cantell K, et al: Topical treatment of fiat vaginal condyloma with human leukocyte interferon, Obstet Gynecol 1984:64:535-538.
37. De Virgilis C, Crippa L, Leopardi O, et al: The role of beta-interferon in the therapy of female genital viral diseases, Int J Immunol 1987:3: 147-150.
38. Schneider A, Papendick U, Gissmann L: Interferon treatment of human genital papillomavirus infections: importance of viral type, Int J Cancer 1987:3:147-150.
39. Syed TA, Cheema KM, Ahmad SA, el al: Human leukocyte interferon-alpha versus podo-phvllotoxin in cream for the treatment of genital warts in males, A placebo-controlled, double-blind, comparative study, Dermatology 1995:191:129-132.
40. Eron LJ, Jodson F, Tucker S, et al: Interferon therapy for condylomata acuminata, N Engl J Med 1986:315:1059-1069.
41. Douglas JM, Rogers U, Judson FN: The effect of asymptomatic infection with HTLV-3 on the response of anogenital warts to intralcsional treatment with recombinant alpha-2-interfer-on, J Infect Dis 1996;154:331-334.
42. Grablowitz D, Micksche M, Soltz-Szots J: Systemic treatment of extcnsic condylomata acuminata with interferon, J Am Acad Dermatol 1992:26:1009-1010.
43. Arany J, Brysk MM, Tyring SK: Response to interferon treatment decreases with epidermal dedifferentiation in condylomas, Antiviral Res 1996:32:19-26.
44. Gross G, Degen KW, Fierlbeck G, et al: Recombinant interferon gamma in anogenital warts: Results of a multicentre placebo-controlled clinical trial, J Interferon Res 1991; 11 (suppl 1):76.
45. Gross G, Ikenberg H, Roussaki A: Systemic treatment of condylomata acuminata with recombinant interferon a!pha-2a: Low-dose superior to high-dose regimen, Chemotherapy 1986:32:537-541.
46. Semprini AE, Stillo A, Marcozzi S, Castagna C, Fiore S, Radaelli U: Treatment with interferon for genital HPV in HIV-positive and HIV-negative women, Eur J Obstet Gyn Reprod Biology 1994:53:135-137.
47. Gross G, Roussaki A, Ikenberg H, Drees N: Genital warts do not respond to systemic recombinant interferon alpha-2a treatment during cannabis consumption, Dcrmatologica 1991;183:203-207.
48. Vance JC, Davis D: Interferon alpha-2b injections used as an adjuvant therapy to carbon dioxide laser vaporization of recalcitrant anogenital condylomata acuminata, J Invest Dermatol 1990:995:146-148.
49. Davis BE, Noble MJ: Initial experience with combined interferon alpha and carbon dioxide laser for the treatment of condylomata acuminata, J Urol 1992;197:627-629.
50. Douglas JM Jr, Eron LJ, Judson FN, et al: A randomized trial of combination therapy with intralesional interferon alpha-2b and podo-phyllin versus podophyllin alone for the therapy of anogenital warts, J Infect Dis 1990:162: 52-59.
51. Handley JM, Horner T, Maw RD, et al: Subcutaneous interferon alpha-2a combined with cryotherapy vs, cryotherapy alone in the treatment of primary anogenital warts: A randomised observer-blind placebo-controlled study, Genilourin Med 1991:67:297-307.
52. Eron LI, Alder MB, O’Rourke JM, et al: Recurrence of condylomata acuminata following cryotherapy is not prevented by systcmicaily administered interferon, Gcnitourin Med 1993:69:91-93.
53. Hohcnleutner U, Landthaler M, Braun-Falco O: PostoperativeadjuvantcThcrapie mil Inter-feron-alpha-2b nach Laserchirurgie von Condylomata acuminata, Hautarzl 1990:41:545-548.
54. Petersen CS, Bjerring P, Larsen J, Blakkaer J: Systemic interferon alpha-2b increases the cure rate in laser-treatment patients with multiple persistent genital warts: a placebo-controlled study, Genitourin Med 1991;67:99-102.
55. The Condylomata International Collaborative Study Group: Randomized placebo-controlled double-blind combined therapy with laser surgery and systemic intcrferon-alpha-2a in the treatment of anogenital condylomata acuminata, J Infect Dis 1993:167:824-829.
56. Niemincn P, Aho M, Lehtincn M, et al: Treatment of genital HPV infection with carbon dioxide laser and systemic interferon alpha 2a, SexTransm Dis 1994:21:59-65.
57. Gross G, Roussaki A, Baur S, et al: Systemical-ly administered interferon alpha-2a prevents recurrence of condylomata acuminata following COj-Iaser ablation, The influence of the cyclic low-dose therapy regimen, Results of a multicentre double-blind placebo-controlled clinical trial, Genitourin Med 1996:72:71.
58. Armstrong DKB, Maw RD, Dinsmore WW, et al: Randomised, double-blind, parallel group study to compare subcutaneous interferon al-pha-2a plus podophyllin w ith placebo plus podophyllin in the treatment of primary condylomata acuminata, Genitourin Med 1994;70: 389-393.
59. Armstrong DKB, Maw RD, Dinsmore WW, et al: Combined therapy trial with interferon al-pha-2a and ablative therapy in the treatment of anogenital warts, Gcnitourin Med 1996:72: 103-107.
60. Dianzani F: Interferon treatments: How to use an endogenous system as a therapeutic agent, J Interferon Res 1992(special issue): 109-118.
61. Priimmer O, Gross G, Baur S, Herrmann F: The beneficial effect of low-dose interferon al-pha-2a treatment in patients with condylomata acuminata is not impaired by interferon-alpha antibodies, J Interferon Cytokine Res in press
62. Berman B, Sequeira M: Dermatologic uses of interferons, Dermatol Clin 1995:13:699-711
63. Gross G, Roussaki A, Brzoska J: Topical interferon beta gel as adjuvant therapy in immunocompromised patients with recurrent genital warts, J Interferon Res 1996; 10 (suppl 1): 112.
64. Gross G, Roussaki A, Brzoska J: Recalcitrant giant molluscum contagiosum in a patient with AIDS successfully treated by a combination of CO; laser Swift Laser™ and natural interferon beta gel, Acta Derm-Vener, submitted
65. Jin Z, Kumar A, Cleveland RP, et al: Inhibition of suppressor cell function by cimetidine in a murine model, Clin Immunol Immunopathol 1986:38:350-356.
66. Strejcek J, Suhajowa E, Jira M, et al: Further evidence of immunomodulartory effects of cimetidine, Allergy Immunol (Leipz) 1984:30: 117-122.
67. Avella J, Madsen JE, Binder HJ, et al: Effect of histamine-reccptor antagonists on delayed hypersensitivity, Lancet 1978:i:624-626.
68. Jorizzo JL, Sams WM, Jegasothv BV, et al: Cimetidine as an immunomodulator: Chronic mucocutaneous candidiasis as a model, Ann Intern Med 1980;92:192-195.
69. Orlow SJ, Paller A: Cimetidine therapy for multiple viral warts in children, J Am Acad Dermatol 1993;28:794-796.
70. Choi YS, Hann SK, Park YK: The effect of cimetidine on verruca plana juvenilis: Clinical trials in six patients, J Dermatol (Tokyo) 1993; 20:497-500.
71. Glass AT, Solomon BA: Cimetidine therapy for recalcitrant warts in adults, Arch Dermatol 1996;132:680-682.
72. Yilmaz E, Alpsoy E, Basaran E: Cimetidine therapy for warts: A placebo-controlled, double-blind study, J Am Acad Dermatol 1986;34: 1005-1007.
73. Davidson-Parker J, Dinsmore W, Khan MH, et al: Immunotherapy of genital warts w ith ino-sinc pranobex and conventional treatment: double blind placebo-controlled study, Geni-tourin Med 1988:64:383-386.
74. Tay SK: Efficacy of inosine pranobex oral therapy in subclinical human papillomavirus infection of the vulva: A randomized doubleblinded placebo controlled study, Intern J STD AIDS 1996;7:276-280.
75. Cunliffe WJ, Miller AJ (eds): Retinoid Therapy, Lancaster, MTP Press, 1984.
76. Lutzncr UA, Blanchet-Bardon C, Orth G: Clinical observations, urologic studies and treatment trials in patients with epidermodysplasia-verruciform is, a disease induced by specific human papillomaviruses, J Invest Dermatol 1984:835:18-25.
77. Gross G, Ellinger K, Roussaki A, Pfistcr H: Epidermodysplasia verruciformis in a patient with Hodgkin's disease: Characterization of a new papillomavirus type and interferon treatment, J Invest Dermatol 1988:91:43-48.
78. Boyle J, Dick DC, Mackie RU: Treatment of extensive virus warts with cturetinate (Tiga-son) in a patient with sarcoidosis, Clin Exp Dermatol 1983:8:33-36.
79. Gross G, Pfistcr H, Hagedorn M, Stahn W: Effect of oral aromatic retinoid (Ro 10-9359) on human papillomavirus-2-induced common warts, Dermatologica 1983; 166:48-53.
80. Majewski S, Jablonska S: Human papillomavirus-associated tumors of the skin and mucosa, J Am Acad Dermatol 1997:36:659-685.
81. Lippmann SM, Kavanagh JJ, Paredes-Espi-noza M: 13-cis-Retinoic acid plus interferon-alpha 2a: Highly active systemic therapy for squamous cell carcinoma of the cervix, J Natl Cancer Inst 1992:84:241-245.
82. Bollag W: Retinoids and interferon: A new-promising combination? Br J Haematol 1991; 79(suppl 1):87-91.
83. Majewski S, Szmurlo A, Marczak M, et al: Inhibition of tumor-cell induced angiogcncsis by retinoids, 1.25-dihydroxyvitamin Diand their combination, Cancer Lett 1993:75:35-39.
84. Majewski S, Skopinska M, Bollag W, et al: Combination of isoretinoin and calcitriol for precanccrous and cancerous skin lesions, Lancet 1994;344:1510-1511.
85. Lowy D, Androphy EJ: Warts; in Fitzpatrick TB, Eiscn AZ, Wolff K, et al: (eds): Dermatology in General Medicine, ed 4. New York, McGraw-Hill, pp 2611-2621.
86. Schiller JT, Okun MM: Papillomavirus vaccines: Current status and future prospects; in Yancey KB (ed): Advances in Dermatology, St, Louis, Mosby-Ycar Book, 1996. vol 11. pp 355-381.
87. Frazer IH: Immunology of papillomavirus infection, CurrOpin Immunol 1996;4:484-491.
88. Frazer IH: The role of vaccines in the control of STDs: HPV vaccines, Genitourin Med 1996: 72:398-403.
89. Bosch FX, Manos MM, Manoz N, et al: Relevance of human papillomavirus in cervical cancer: A worldwide perspective, J Natl Cancer Invest 1995:87:796-799.
90. Parkin DM: Cancer in developing countries, Cancer Surv 1994; 19-20:519-561.
91. Moy R, Eliezri YD: Significance of human papillomavirus-induced squamous-cell carcinoma to dermatology, Arch Dermatol 1994:130:235-237.
92. Penn I: Skin disorders in organ transplant recipients, External anogenital lesions, Arch Dermatol 1997;133:221-235.